Diabetes News Archive
Median of 2 strips/day used by those taking agents not considered to be risk for causing hypoglycemia
Rate has declined but remains higher in those with type 1 or 2 diabetes than in those without
Linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk for a composite cardiovascular or renal outcome over a median 2.2 years.
Prediction independent of traditional risk factors such as MetS, glucose, HbA1c in general population
Significant additive interaction identified for night shift work, unhealthy lifestyle for female nurses
Report provides guidance on reducing CV risk in patients with T2DM and atherosclerotic CV disease
Using higher HbA1c target in over-75s could increase disability-adjusted life-years by 44.2%.
Delays in seeking care for first major symptom of macrovascular disease, first major diagnostic test.
SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients with type 2 diabetes.
Risk increased for lower-limb amputation, diabetic ketoacidosis compared with GLP1 receptor agonists.
Lower all-cause mortality in CABG group vs PCI-DES group after median follow-up of 7.5 years.
For patients with prediabetes, changes in risk indicators during intervention tied to T2DM, CVD risk
Treatment resulted in lower HF hospitalization rate in patients with, without atherosclerosis.
Treatment with bardoxolone methyl resulted in significant weight loss and showed no evidence of muscle wasting in patients with type 2 diabetes and stage IV chronic kidney disease.
Strict BP control, fenofibrate use may increase long-term risk for adverse kidney events in T2DM patients
In a study, reduced mortality was found among TRT users with type 2 diabetes after adjustment for cardiovascular risk factors.
The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults with T2D who had established CV disease or were at risk for CV disease with ≥2 risk factors.
Canagliflozin vs placebo is associated with increased survival and renal outcomes in patients with type 2 diabetes and macroalbuminuria.
Fasting plasma glucose, BMI elevated 10 years before diagnosis of prediabetes, diabetes.
Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.
Additional focus on lifestyle management, self-management education and support emphasized
Findings based on data reweighted to reflect the adult population with diabetes in the US.
Lixisenatide reduces progression of urinary albumin-creatinine ratio in patients with macroalbuminuria.
Despite having been withdrawn, albiglutide is superior to placebo for reducing cardiovascular events
Finnish study of individuals with type 2 diabetes reveals a 17% and 42% higher incidence of bladder and kidney cancer, respectively, compared with the general population.
New study reveals a type 2 diabetes incidence rate of 17.81 cases per 1000 person-years, a rate much higher than in the general population.
Highest vs lowest quartile of serum phosphorus is independently associated with a nearly 3-fold increased risk of diabetic nephropathy progression.
Among US dialysis patients, cardiovascular event rates are highest in those with diabetic nephropathy and lowest among those with IgA nephropathy.
Measurement of plasma copeptin better than water-deprivation test in patients with hypotonic polyuria.
A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.
Associated with increased risk of myocardial infarction, all-cause mortality, severe hypoglycemia.
In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.
Changes will describe hypoglycemic coma and clarify and identify mental health side effects.
Increased risk seen for women but not men; slightly attenuated after adjustment for mediating factors.
Eversense CGM, which has fully implantable sensor to detect glucose, approved for adults with diabetes.
Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.
Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist.
Better glycemic control than conventional subcutaneous insulin therapy in patients with T2DM.
In subgroup analyses, reduced incidence of cancer seen in participants aged younger than 65 years.
Target HbA1c 7 to 8 for most patients with T2DM; deintensification of tx with HbA1c 6.5
Independently linked to major cardiovascular events, especially heart failure hospitalizations.
Medication reconciliation linked to lower risk of combined ER visits, hospitalization over 6 months.
In a South Korean study, nearly 60% of elderly patients with type 2 diabetes had chronic kidney disease at baseline.
Patients with higher levels of serum fibrinogen have higher rates of progression.
Increased risk of subsequent diabetes independent of traditional diabetes risk factors.
Much steeper decline in adjusted mean eGFR for those with diagnosed diabetes versus those without.
New study shows metformin is not associated with an increased risk of acidosis in patients with type 2 diabetes and an eGFR of 30 to 60 mL/min/1.73 m2.
Within 6 months of elevated HbA1c, rate of initiation 63%, rate of intensification 82%.
Type 2 diabetes is among the leading causes of end-stage renal disease (ESRD), but the estimated cumulative risk of ESRD at 20 years after diagnosis of type 2 diabetes is less than 1%.
Decrease in length of stay and mortality, but increase in mean hospital charges during study period.
Women who had gestational diabetes more likely to show increased eGFR levels many years postpartum
Genome-wide association study identified novel signal near GABRR1, which was not seen in Asians.
Frequency of primary outcome was 27.6 and 23.4% in glyburide and insulin groups, respectively.
Major adverse CV and cerebrovascular events with noncardiac sx have also increased in DM patients
Aortic distensibility independently linked to concentric left ventricular remodeling
Breakfast time mediates the association between morning-evening preference and BMI
Overall, 21, 29, and 13% meet goals for fruit, vegetable, and dairy intake, respectively
Increased risk of CVD for achieved systolic blood pressure of 120 versus 130 or 140 mm Hg
In a study of patients with type 2 diabetes, researchers observed a significantly lower annual decline in estimated glomerular filtration rate among those treated with fenofibrates vs placebo.
In a survey, nearly one-third of hemodialysis patients said they disliked fluid restriction.
Among adults with heart disease, risk increased with DPP-4I vs thiazolidinedione not sulfonylureas
DM tied to 6-month mortality, major complications, ICU admission, mechanical ventilation, LOS
10-year lifestyle, weight loss changes increased disability-free years in women, those without CVD
Higher risk of inflammatory bowel disease with longer use of dipeptidyl peptidase-4 inhibitor
AKI hospitalizations were 4 times more likely among patients with diabetes.
Using open flames or high temps to cook red meat, chicken both linked to higher risk of T2DM
However, more data is needed on the long-term safety of chronic intranasal insulin administration
Clinicians should personalize glycemic control goals; aim for HbA1c of 7 to 8% for most adults.
These clusters show differing disease progression and risk of diabetic complications
Treatment effect is greater in patients with dyslipidemia; absolute risk reduction of 2.15%
Earlier diagnosis of T2DM tied to increased mortality, mainly driven by cardiovascular disease mortality
The percentage decline in estimated glomerular filtration rate over an 8-year period was greater among those with vs without diabetes across all quintiles of protein intake.
Prediabetes measured by FPG, 2-hour plasma glucose not linked to increased risk of major event.
A1C is not associated with increased 30-day mortality after controlling for glucose
Improvement in glycemic control, reduction in body weight, SBP; increase in genital mycotic infections.
Working more night shifts per month linked to increased odds of type 2 diabetes
Subtle elevations in fasting glucose and triglycerides associated with developing type 2 diabetes
Mortality rates increasing among those with albumin-to-creatinine ratio 30 mg/g and low eGFR
Risk scores summarizing 8 diseases, markers tied to cancer risk in dose-response manner
Also linked to increased rate of hospitalization; very few receive help with housing through their clinic
Findings demonstrate an important population burden, including hospitalization and death.
AKI associated with 27% increased risk of hypoglycemia among patients with diabetes.
Diabetes and prediabetes duration also tied to worse subclinical systolic function, diastolic relaxation.
Nadir at BMI of 25 to 30 kg/m stepwise increase to peak for patients with BMI 40 kg/m
System allows glucose-responsive, closed-loop release to improve therapeutic performance of Ex4.
Relative risk of end-stage renal disease was 0.13 in those diagnosed in 1995-2011 versus 1965-1979.
Over 20% of US veterans were diagnosed with diabetes from 2013 to 2014.
Newly diagnosed T2D patients who strictly maintain glycemic targets may go into remission in 1 year.
Reduced incidence seen with lifestyle changes, meds; however, effect of meds is short-lived.
Mineralocorticoid receptor antagonists found to lower hospital readmission risk in patients with heart failure and concomitant diabetes or renal insufficiency.
Delayed-release Niacin may be beneficial to patients with prediabetes and type 2 diabetes.
Saturated fat intake significantly decreases in HbA1c-lowering effect in DPP4i monotherapy in patients with diabetes.
Intensive BP drops may lower cardiovascular risks in both patients with and without diabetes.
In patients with T2DM, taking liraglutide before surgery may be associated with reduced post-op plasma glucose levels.
Atherothrombotic disease risk assessment based upon 10 readily available clinical variables.
Measuring the quality of life and status of health is imperative in patients with diabetes.
The FDA just approved a new short-acting insulin drug, Admelog, for patients with either T1D or T2D.
Remission was linked to 46% patients in intensive weight management programs.
Semaglutide helps patients with diabetes reduce blood glucose levels and lower body weight.
Lifestyle and clinical factors could have been misinterpreted, linking antibiotics to risk of diabetes.
Renal and Urology News Articles
- Obesity Linked With Improved Survival in mCRPC
- Radium-223 Use in mCRPC Differs By Race
- Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline
- Kidney Damage in Younger Adults Tied to NSAID Use
- Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)